在接受初级皮肤冠状动脉干预的ST段升高心肌梗塞患者中使用蒂卡格勒或普拉苏格勒
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
在PubMed上查看摘要
概括
此摘要是机器生成的。在ST段升高心肌梗塞患者接受初级皮肤冠状动脉干预时,提卡格勒和普拉苏格勒的疗效相似. 然而,与普拉苏格勒相比,提卡格勒与心肌梗塞复发的风险更高.
科学领域
- 心脏病学
- 干预心脏病学
- 药理学
背景情况
- 在ST段升高心肌梗塞 (STEMI) 患者接受初级穿皮冠状动脉干预 (PCI) 时,关于提卡格勒勒与普拉苏格勒的数据有限.
- 这项研究提供了这些抗血小板药物在特定高风险患者群体中的对比.
研究的目的
- 在接受初级PCI的STEMI患者中,比较蒂卡格勒罗与普拉苏格勒的疗效和安全性.
- 评估两个治疗组之间主要心血管不良事件和出血的发生率.
主要方法
- 在ISAR REACT-5试验中对1653名STEMI患者进行了小组分析.
- 患者被随机分为接受蒂卡格勒或普拉苏格勒.
- 主要终点:死亡,1年内心肌梗塞或中风. 二次终点:学术研究联盟 (BARC) 发现在1年后的3-5型出血.
主要成果
- 在Ticagrelor和Prasugrel组之间没有发现主要终点 (死亡,心脏病发作或中风组合) 的显著差异 (10. 1% vs 7. 9%,P=0. 10).
- 与普拉苏格勒相比,提卡与心肌梗塞的发生率显著增加 (5. 3% 与 2. 8% 相比,P=0. 010).
- 死亡率,中风,支架血栓和BARC 3-5型出血在两组之间没有显著差异.
结论
- 在接受初级PCI的STEMI患者中,Prasugrel和Ticagrelor在初级复合终点上表现出可比的整体疗效.
- 使用提卡与心肌梗塞复发的风险增加有关.
- 在这种情况下,选择蒂卡格勒和普拉苏格勒需要仔细考虑个体患者的风险因素.
相关概念视频
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...